<DOC>
	<DOCNO>NCT00818831</DOCNO>
	<brief_summary>The purpose trial : - To evaluate toxicity tolerability QBI-139 patient advance refractory solid tumor . - To determine maximum tolerate dose QBI-139 patient advance , refractory solid tumor . Patients receive QBI-139 IV infusion least one hour weekly three week . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3 6 patient receive escalate dos QBI-139 maximum tolerate dose ( MTD ) determine .</brief_summary>
	<brief_title>A Study QBI-139 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects must refractory intolerant establish therapy know provide clinical benefit condition , i.e. , patient must candidate regimen know provide clinical benefit . Patients must measurable ( define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ) solid tumor . Prior chemotherapy radiation therapy allow ( least 4 week must pass prior chemotherapy radiotherapy ( 6 week nitrosoureas mitomycin C ) ) , provide clinically significant toxicity relate prior chemotherapy radiotherapy return baseline National Cancer Institute ( NCI ) Common Toxicity Adverse Events ( CTCAE ) grade ≤ 2 expect recover . The toxicity specifically exclude alopecia . Age &gt; 18 year . ECOG performance status &lt; 2 . Life expectancy great 12 week , estimate Principal Investigator . Patients must normal organ marrow function define protocol . The effect QBI139 develop human fetus unknown . Therefore , men woman attempt conceive woman pregnant breastfeed take part study ( 90 day complete study ) . Ability understand willingness sign write informed consent document . Concurrent treatment investigational agent investigational agent ( ) use study OR treatment within 4 week study entry investigational agent ( ) device ( ) . Failure recover fully ( judged Investigator ) prior surgical procedure . Patients know brain metastasis leptomeningeal carcinomatosis Patients gastrointestinal bleed require transfusion within past 6 month active Grade 2 high diarrhea Treatment Ranpirnase ( Onconase® ) Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Women pregnant breastfeeding Patients know HIV ineligible Patients know immunocompromised status organ transplant exclude Patients must : unstable angina ( anginal symptom rest ) within past 6 month myocardial infarction within past 6 month new onset angina within last 3 month . QT prolongation ( define QTc &gt; 450 msec male QTc &gt; 470 msec female )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Advanced , refractory solid tumor</keyword>
</DOC>